register

News & Trends - Pharmaceuticals

Clinically superior and fast-acting vitamin D launches in Australia

Health Industry Hub | March 3, 2021 |

To address global concerns and needs in supporting immune health, Royal DSM, a global science-based company, launched ampli-D, a fast-acting and highly potent form of Vitamin D for dietary supplements in Australia.

ampli-D is a faster and more effective way for Australians to boost Vitamin D levels in the body in just days and weeks instead of months to support immune health.

The availability of DSM’s ampli-D in Australia, the first market for its launch, follows regulatory approval by Australia’s Therapeutic Goods Administration (TGA) for its use in dietary supplements that do not require a prescription.

Despite its importance to health and well-being, Vitamin D deficiency is a prevalent global health issue and more than 80% of the world’s population have sub-optimal levels of Vitamin D in their body. Even in sunny Australia, the Australian Bureau of Statistics (ABS) calculated that one in five Australian adults are deficient in Vitamin D and an additional 43% have sub-optimal levels.

Interview links will be provided via email next week.

“Vitamin D is typically obtained through sunlight, diet and supplements but many people don’t realise that they don’t get enough and quickly enough. With today’s concerns on health and well-being, Vitamin D is an important micronutrient that helps to enhance immune system function, and emerging scientific evidence supports the important role of Vitamin D in the body’s response in resolving and lowering the risk of acute respiratory tract infections,” said Dr Michela Sorensen, Australian GP.

Getting to sufficient levels of vitamin D in the body can be challenging due to limited food sources and a person’s direct exposure to sunlight which is affected by the seasons throughout the year, skin colour, and use of protective clothing and sun protection. Even with an intake of traditional Vitamin D supplements like D3 or fortified food, it can still take several months to achieve healthy Vitamin D levels in the bloodstream.

Peter Van Dael, SVP Nutrition Science at DSM, explains “In the human body, Vitamin D needs to be first processed by the liver and converted into Calcifediol to be processed further in the kidneys. The whole process is slow and it can easily take several months to achieve healthy levels in the bloodstream. With ampli-D, Calcifediol or 25-Hydroxyvitamin D3, the common form of Vitamin D in the body is now also available as a dietary supplement. Research and clinical studies have shown that ampli-D works three times faster and more effectively than conventional Vitamin D3 supplements, helping the body get to optimal Vitamin D levels in days and weeks instead of months.”

Recent events have also put a spotlight on the importance of a strong and healthy immune system. In a recent consumer study conducted by DSM in 2020 with 12,000 participants across 24 countries, 65% of the global participants ranked immunity as one of their top 3 health concerns.

Carmel Power, Head of Human Nutrition, Oceania at DSM said, “Supporting our immune health is important throughout our lives and it is more important than ever to do it more effectively with the emergence of new threats to human health. DSM is committed to addressing global health concerns such as immunity and keeping the growing global population healthy. The introduction of ampli-D in Australia shows how we want to champion this purpose – by accelerating the availability of our industry-leading nutritional solutions through market-ready solutions for our partners and consumers.”

Leading DSM customer, Factors Group has recently launched Opti Active D containing ampli-D, under their practitioner-only range of evidence based dietary supplements, Bioclinic Naturals.

In addition, DSM has also launched its own dietary supplement product with ampli-D in tablet form for Australian consumers, branded as FORTARO. It Is available for purchase on fortaro.com


News & Trends - Pharmaceuticals

March PBAC agenda unveiled amid tensions over 'unprecedented' volume of submissions

March PBAC agenda unveiled amid tensions over ‘unprecedented’ volume of submissions

Health Industry Hub | November 29, 2024 |

The Department of Health has released the agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting, unveiling plans […]

More


News & Trends - MedTech & Diagnostics

Johnson & Johnson MedTech exits DePuy Synthes spine portfolio

J&J MedTech exits DePuy Synthes spine portfolio

Health Industry Hub | November 29, 2024 |

Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of […]

More


News & Trends - Pharmaceuticals

Home-grown hypertension polypill heads for regulatory approval

Home-grown hypertension polypill heads to regulatory approval

Health Industry Hub | November 29, 2024 |

Australian-supported research has revealed remarkable Phase III clinical trial results for an innovative triple drug combination in the treatment of […]

More


News & Trends - Pharmaceuticals

Will Australia become first country to eliminate HIV transmission by 2030?

Will Australia become first country to eliminate HIV transmission by 2030?

Health Industry Hub | November 29, 2024 |

In the lead-up to World AIDS Day on December 1, the Albanese Government has unveiled the 9th National HIV Strategy, […]

More


This content is copyright protected. Please subscribe to gain access.